168 related articles for article (PubMed ID: 36220782)
1. Characterization of cellular phenotypes in neurons derived from induced pluripotent stem cells of male patients with Fabry disease.
Miyajima T; Saito R; Yanagisawa H; Igarashi M; Wu C; Iwamoto T; Eto Y
J Inherit Metab Dis; 2023 Jan; 46(1):143-152. PubMed ID: 36220782
[TBL] [Abstract][Full Text] [Related]
2. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
3. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
4. Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells.
Tseng WL; Chou SJ; Chiang HC; Wang ML; Chien CS; Chen KH; Leu HB; Wang CY; Chang YL; Liu YY; Jong YJ; Lin SZ; Chiou SH; Lin SJ; Yu WC
Cell Transplant; 2017 Mar; 26(3):513-527. PubMed ID: 27938475
[TBL] [Abstract][Full Text] [Related]
5. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
6. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.
Chou SJ; Yu WC; Chang YL; Chen WY; Chang WC; Chien Y; Yen JC; Liu YY; Chen SJ; Wang CY; Chen YH; Niu DM; Lin SJ; Chen JW; Chiou SH; Leu HB
Int J Cardiol; 2017 Apr; 232():255-263. PubMed ID: 28082092
[TBL] [Abstract][Full Text] [Related]
7. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
[TBL] [Abstract][Full Text] [Related]
8. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Choi JB; Seol DW; Do HS; Yang HY; Kim TM; Byun YG; Park JM; Choi J; Hong SP; Chung WS; Suh JM; Koh GY; Lee BH; Wee G; Han YM
Mol Ther; 2023 Apr; 31(4):1002-1016. PubMed ID: 36755495
[TBL] [Abstract][Full Text] [Related]
9. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356
[TBL] [Abstract][Full Text] [Related]
10. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.
Valbuena C; Leitão D; Carneiro F; Oliveira JP
Virchows Arch; 2012 Feb; 460(2):211-21. PubMed ID: 22205110
[TBL] [Abstract][Full Text] [Related]
12. Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse.
Cortés-Saladelafont E; Fernández-Martín J; Ortolano S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982318
[TBL] [Abstract][Full Text] [Related]
13. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
[TBL] [Abstract][Full Text] [Related]
14.
Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
[TBL] [Abstract][Full Text] [Related]
15. Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy.
Liguori R; Incensi A; de Pasqua S; Mignani R; Fileccia E; Santostefano M; Biagini E; Rapezzi C; Palmieri S; Romani I; Borsini W; Burlina A; Bombardi R; Caprini M; Avoni P; Donadio V
PLoS One; 2017; 12(7):e0180581. PubMed ID: 28672034
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.
Varela P; Carvalho G; Martin RP; Pesquero JB
Metab Brain Dis; 2021 Feb; 36(2):265-272. PubMed ID: 33156427
[TBL] [Abstract][Full Text] [Related]
17. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
18. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.
Ter Huurne M; Parker BL; Liu NQ; Qian EL; Vivien C; Karavendzas K; Mills RJ; Saville JT; Abu-Bonsrah D; Wise AF; Hudson JE; Talbot AS; Finn PF; Martini PGV; Fuller M; Ricardo SD; Watt KI; Nicholls KM; Porrello ER; Elliott DA
Am J Hum Genet; 2023 Sep; 110(9):1600-1605. PubMed ID: 37607539
[TBL] [Abstract][Full Text] [Related]
19. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
[TBL] [Abstract][Full Text] [Related]
20. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]